Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (1)
  • Closed (3)

Medical Condition

  • Show all (187)
  • Autoimmune Disorders (3)
  • Blood Disorders (9)
  • Cancer (113)
    • Bladder Cancer (1)
    • (-) Brain Cancer (2)
    • Breast Cancer (2)
    • Gastrointestinal (3)
    • Gynecologic Cancer (4)
    • Head and Neck Cancer (2)
    • Kidney Cancer (3)
    • Leukemia (10)
    • Liver Cancer (1)
    • Lung Cancer (14)
    • Lymphoma (8)
    • Multiple Myeloma (6)
    • Pancreatic Cancer (1)
    • Prostate Cancer (9)
    • Sarcoma (4)
    • Skin Cancer (5)
    • Solid Tumors (7)
  • Diabetes (1)
  • Healthy Volunteers (4)
  • Heart Disease (2)
  • Infectious Disease (3)
  • Neurological Disorders (17)
    • Brain Tumors (11)
    • Multiple Sclerosis (1)
    • (-) Neuromuscular (2)
  • Nutrition (1)
  • Obstetrics & Gynecology (1)
  • Pediatrics (15)
  • Psychiatric Disorders (1)
  • Transplant (16)
  • Urology (1)
Displaying 1 - 4 of 4

Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)

Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Read More

Study of Pemigatinib in Patients with Glioblastoma (GBM) or Other CNS Tumors

Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Read More

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
This study is designed to test how well an intravenous human immunoglobulin concentrate, IGIV-C (compared with placebo) improves the ability to taper participant's dose of corticosteroids without causing significant increase in your muscle weakness and worsening MG symptoms. A placebo is a medication that looks like the study medication but has no active…
Read More

A Study for Patients With Generalized Myasthenia Gravis Using Intravenous Human Immunoglobulin Concentrate, IGIV-C.

Condition: Neurological Disorders / Neuromuscular
Investigator: Thomas Brannagan, MD
Status: Closed
This study is designed to test how well an intravenous human immunoglobulin concentrate, IGIV-C (compared with placebo) improves your muscle weakness associated with MG symptoms. A placebo is a medication that looks like the study medication but has no active ingredient. Immunoglobulin is an antibody produced by white blood cell…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science